What is more, Wong et al. (2010) showed that down-regulation of CD200 expression on tumor cells may improve immunogenicity of CLL and lymphoma cells and enhances the efficacy of cell-based immunotherapies. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.